[
    "{\"step_by_step_thinking\": \"Based on the information provided in the relevant documents, Zanubrutinib is not a first-generation BTK inhibitor approved by the US Food and Drug Administration (FDA). It is described as a second-generation BTK inhibitor and has been approved by the FDA for the treatment of mantle cell lymphoma (MCL), Waldenstr\u00f6m macroglobulinemia (WM), and marginal zone lymphoma (MZL).\", \"answer_choice\": \"B\"}"
]